title: Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer.
abstract: OBJECTIVE
  We evaluated the independent response rate of dexamethasone before docetaxel and estramustine administration as measured by changes in serum prostate specific antigen (PSA) in patients with androgen independent prostate cancer.
  
  
  METHODS
  A total of 12 patients received 20 mg. dexamethasone orally every 6 hours for 3 doses repeated every 3 weeks before starting cytotoxic therapy with estramustine and docetaxel. After progression on dexamethasone 280 mg. estramustine orally 3 times daily on days 1 to 5 and 70 mg./m.2 docetaxel intravenously for 1 hour on day 2 were given.
  
  
  RESULTS
  None of the patients initially treated with dexamethasone monotherapy (median 1 cycle, range 1 to 5) had a PSA decline of 50% or greater. Median PSA increase on monotherapy was 47% (range 0% to 22%). On estramustine and docetaxel therapy PSA decreased 50% or greater in 11 patients (92%, 95% confidence intervals [CI] 60 to 99) and 80% or greater in 7 (58%, 95% CI 29 to 84), and normalized in 5 (42%, 95% CI 16 to 71), with a median duration of response of 153 (range 42 to 371), 132 (range 84 to 287) and 84 (range 21 to 174) days, respectively. Median times to reach 50% and 80% decreases in baseline PSA were 21 (range 21 to 209) and 63 (range 21 to 138) days, respectively. In 9 patients (75%, 95% CI 43 to 93) PSA decreased at least 50% by week 9. Of 4 patients with bidimensionally measurable disease 3 had a partial response. Median time to progression was 263 days (range 91 to 378).
  
  
  CONCLUSIONS
  Administration of 20. mg. dexamethasone orally every 6 hours for 3 doses every 3 weeks does not significantly contribute to the PSA response rate of estramustine and docetaxel.
authors.affiliation: Department of Medicine, Columbia Presbyterian Medical Center, New York, New York 10032, USA.
authors.forename: A L
authors.initials: AL
authors.lastname: Weitzman
authors.forename: G
authors.initials: G
authors.lastname: Shelton
authors.forename: N
authors.initials: N
authors.lastname: Zuech
authors.forename: C E
authors.initials: CE
authors.lastname: Owen
authors.forename: T
authors.initials: T
authors.lastname: Judge
authors.forename: M
authors.initials: M
authors.lastname: Benson
authors.forename: I
authors.initials: I
authors.lastname: Sawczuk
authors.forename: A
authors.initials: A
authors.lastname: Katz
authors.forename: C A
authors.initials: CA
authors.lastname: Olsson
authors.forename: E
authors.initials: E
authors.lastname: Bagiella
authors.forename: C
authors.initials: C
authors.lastname: Pfaff
authors.forename: J H
authors.initials: JH
authors.lastname: Newhouse
authors.forename: D P
authors.initials: DP
authors.lastname: Petrylak
mesh_terms: D000230:Adenocarcinoma / Q000097:blood*; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D003907:Dexamethasone / Q000008:administration & dosage*; D000077143:Docetaxel; D004334:Drug Administration Schedule; D004961:Estramustine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy*; D043823:Taxoids
chemical_list: D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D004961:Estramustine; D003907:Dexamethasone; D017430:Prostate-Specific Antigen; D017239:Paclitaxel